Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

15.73 -0.10 (-0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
From Rallybio Corporation
Via Business Wire
News headline image
Where Rallybio Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Ratings for Rallybio ↗
 
Via Benzinga
News headline image
Analyst Ratings for Rallybio ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Rallybio ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
News headline image
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at Upcoming Investor Conferences in September
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
News headline image
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for... 
Via Benzinga
News headline image
Rallybio to Present at the Jefferies Healthcare Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports First Quarter 2023 Financial Results
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
From Rallybio Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023 ↗
 
Via Benzinga
News headline image
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
From Rallybio Corporation
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time for another dive into the biggest pre-market stock movers for Thursday with all the companies traders need to watch! 
Via InvestorPlace
News headline image
Rallybio Pulls Plug On One Candidate After Highlighting Encouraging Data From Another Thrombocytopenia Program ↗
 
Via Benzinga
News headline image
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
News headline image
EyePoint Pharma Posts Deeper Losses For Q4, Expects Cash Runway Into 2024 ↗
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported Q4 revenues of $10.5 million, down 8.8% Y/Y, almost in line with the consensus of $10.40 million. 
Via Benzinga
News headline image
Rallybio to Present at Upcoming Investor Conferences in March
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.